Corium Launches ADLARITY® (donepezil transdermal system) for Patients with Alzheimer’s Dementia

First once-weekly transdermal system offering continuous delivery of donepezil, most-commonly prescribed Alzheimer’s dementia drug

Broadens Corium’s CNS drug portfolio

Excerpt from the Press Release:

BOSTON, Sept. 29, 2022 /PRNewswire/ — Corium, Inc., a fully-integrated biopharmaceutical company leading the development and commercialization of novel central nervous system (CNS) therapies, announced today that ADLARITY (donepezil transdermal system) is now available for prescription in the U.S. for the treatment of patients with mild, moderate, or severe dementia of the Alzheimer’s type.

ADLARITY, approved by the U.S. Food and Drug Administration in March 2022, is the first and only once-weekly patch to continuously deliver consistent doses of donepezil through the skin, enabling a favorable overall gastrointestinal (GI) side effect profile. Donepezil, an acetylcholinesterase inhibitor and the active ingredient in the oral medication Aricept®, is the most prescribed Alzheimer’s dementia medication. Patients may be switched by their prescriber from a daily 5 mg or 10 mg dose of oral donepezil directly to the once-weekly ADLARITY, which is available in daily 5 mg or 10 mg transdermal formulations.

“We are thrilled to be launching ADLARITY and feel fortunate for the opportunity to provide patients living with Alzheimer’s dementia, their families, and their caregivers a new, innovative way to deliver donepezil in a consistent and well-tolerated option,” said Perry Sternberg, President and Chief Executive Officer of Corium. “The launch of ADLARITY demonstrates the value of Corium’s innovative CORPLEX™ technology and our commitment to providing treatment options that address unmet needs for CNS conditions. I want to thank our people, whose tireless commitment made the possibility of helping millions of people in the U.S. living with Alzheimer’s disease a reality.”

Click the button below to read the entire Press Release:

Continue Reading The Press Release